Strategic partnership ProtaGene has recently formed a strategic partnership with Merck/MilliporeSigma to offer end-to-end testing across the biopharmaceutical product lifecycle, indicating an opportunity to position complementary analytic services for customers pursuing integrated development and quality assurance solutions.

Biologics and gene therapy focus With deep expertise in protein analytics and gene/cell therapy platforms, ProtaGene serves high-growth biologics and ATMP segments, suggesting sales opportunities around early-stage to GMP release testing, vector safety, integration site analysis, and bioinformatics-enabled analytics.

Global CRO capability Operating four sites in Europe and North America and serving leading biopharma and gene therapy companies, ProtaGene offers scale and reach that can be leveraged to win multi-region studies, harmonized testing programs, and expedited timelines.

Leadership and expansion Frequent leadership appointments and a history of analytics leadership imply a growing organization open to expanding offerings; target conversations could emphasize expanded services, new platforms, and enhanced data solutions for complex biologics programs.

Moderate revenue, high value With a revenue range of 25–50 million and a specialized high-value service area, ProtaGene represents opportunities for premium, high-margin testing packages, repeatable engagement models, and long-term partnerships with biopharma customers seeking comprehensive analytics.